Video

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

Hristos Kaimakliotis, MD, assistant professor, Indiana University School of Medicine, discusses predictive markers in bladder cancer.

Homologous recombination repair-deficiency (HRD) and cell cycle progression (CCP) have been identified in DNA repair pathways as potential predictors of tumor behaviors, says Kaimakliotis.

After investigating HRD and CCP assays, it was determined that higher CCP and HRD scores were associated with pathological complete responses (pCR) and decreased risk of recurrence.

In a mutation analysis, it was determined that P53 and RB1 mutations were associate with pCRs as well.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD